Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

NCT03379428 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT03379428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03379428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Lead sponsor
US Oncology Research
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 29, 2017
Completion date
January 31, 2025
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, malignant neoplasm of breast